MX

MagnaChip Semiconductor Corp

3.30

Sep 25 • 3:59 PM ET +0.12 (3.77%)

3.79

Aftermarket • 7:59 PM ET +0.49 (14.73%)

Technology Semiconductors South Korea Micro NYSE

Today, 5:31 PMCEO open-market buy of 100,000 shares sends MagnaChip up 20% after hours

Peers: QUIK VLN GSIT CEVA POET HIMX WOLF LASR MTSI SIMO

| Held by: DFMC DFAS AVSC BUSM GWX BSVO AVUS DFUS DXUV DCOR

Index	-
Market Cap	120.48M
Enterprise Value	75.70M
Income	-30.63M
Sales	178.26M
Book/sh	6.20
Cash/sh	2.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	711
IPO	Mar 11, 2011

P/E	-
Forward P/E	-
PEG	-
P/S	0.68
P/B	0.53
P/C	1.37
P/FCF	-
EV/EBITDA	-
EV/Sales	0.42
Quick Ratio	1.92
Current Ratio	2.43
Debt/Eq	0.19
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	-0.85
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-66.07% -
Sales past 3/5Y	-19.60% -18.67%
EPS Y/Y TTM	8.69%
Sales Y/Y TTM	-18.29%
EPS Q/Q	-1601.14%
Sales Q/Q	-2.29%
Earnings	Jul 29 AMC
EPS/Sales Surpr.	- -

Insider Own	23.93%
Insider Trans	1.16%
Inst Own	38.73%
Inst Trans	-8.72%
ROA	-9.12%
ROE	-12.76%
ROIC	-12.63%
Gross Margin	16.26%
Oper. Margin	-20.37%
Profit Margin	-17.18%
SMA20	8.57%
SMA50	-0.45%
SMA200	-9.18%
Trades

Shs Outstand	36.51M
Shs Float	27.77M
Short Float	4.37%
Short Ratio	1.41
Short Interest	1.21M
52W High	9.86 -66.53%
52W Low	2.18 51.38%
Volatility	6.39% 4.28%
ATR (14)	0.19
RSI (14)	55.41
Beta	1.68
Rel Volume	5.19
Avg Volume	857.43K
Volume	4,447,337

Perf Week	20.00%
Perf Month	1.23%
Perf Quarter	-29.03%
Perf Half Y	16.20%
Perf YTD	29.41%
Perf Year	3.45%
Perf 3Y	-57.36%
Perf 5Y	-81.64%
Perf 10Y	-58.44%
Recom	1.00
Target Price	4.00
Prev Close	3.18
Price	3.30
Change %	3.77%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-21	Resumed	Oppenheimer	Perform
Jan-13-21	Reiterated	Needham	Buy	$18 → $25
Jan-08-21	Initiated	Oppenheimer	Outperform	$21
Aug-07-17	Reiterated	Citigroup	Neutral	$10.50 → $11
May-10-17	Initiated	Citigroup	Neutral
Jan-13-17	Upgrade	Needham	Hold → Buy	$10
Sep-29-16	Initiated	ROTH Capital	Buy
May-06-16	Reiterated	Topeka Capital Markets	Buy	$5 → $6
Feb-18-16	Reiterated	Topeka Capital Markets	Buy	$8 → $5
Oct-30-15	Reiterated	Topeka Capital Markets	Buy	$14 → $8
Aug-07-15	Reiterated	Topeka Capital Markets	Buy	$9 → $14
Jun-01-15	Resumed	Needham	Hold
May-29-15	Upgrade	Topeka Capital Markets	Hold → Buy	$9
Feb-13-15	Downgrade	Topeka Capital Markets	Buy → Hold	$14 → $9
Apr-01-14	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-13-13	Reiterated	Barclays	Overweight	$20 → $26
Jul-16-13	Reiterated	Needham	Strong Buy	$24 → $28
May-01-13	Reiterated	Chardan Capital Markets	Buy	$23 → $25
Jan-31-13	Reiterated	Deutsche Bank	Buy	$18 → $20
Jan-31-13	Reiterated	Chardan Capital Markets	Buy	$21 → $23

Show Previous Ratings

Sep-21-26 08:40AM	Magnachip Shares Rise 14% After Securing $5 Million Investment From Navitas (InvestorsHub) +16.36%
07:00AM	Magnachip Announces Strategic Investment by Navitas Semiconductor (Business Wire)
Jul-30-26 08:30AM	Magnachip Semiconductor Corporation Q2 2026 Earnings Call Summary (Moby) +5.65%
Jul-29-26 04:41PM	Magnachip: Q2 Earnings Snapshot (Associated Press) -6.81%
04:01PM	Magnachip Reports Results for Second Quarter 2026 (Business Wire)
04:01PM	Loading…
Jul-08-26 04:01PM	Magnachip to Announce Second Quarter 2026 Financial Results on July 29, 2026 (Business Wire) +14.95%
Jun-29-26 04:01PM	Magnachip Appoints Chae Lee as Chief Executive Officer (Business Wire)
Jun-22-26 04:15PM	Magnachip Launches New 6th-Generation 600V SJ MOSFETs for AI Servers and EV Charging Applications (Business Wire) -9.38%
May-29-26 06:51AM	MX Stock Heads For 29-Month Highs Whats The AI Server Portfolio Showcase That Investors Are Bullish About? (Stocktwits) +29.60%
Apr-29-26 08:30AM	Magnachip Semiconductor Corporation Q1 2026 Earnings Call Summary (Moby) -31.83%
03:10AM	MagnaChip Semiconductor Corp (MX) Q1 2026 Earnings Call Highlights: Revenue Growth Amidst ... (GuruFocus.com)
Apr-28-26 04:19PM	Magnachip: Q1 Earnings Snapshot (Associated Press) -6.53%
04:01PM	Magnachip Reports Results for First Quarter 2026 (Business Wire)
Apr-21-26 06:55AM	Magnachip Launches 8th-generation Ultra Low-Rss(on) 12V BatteryFET Designed for Smartphone Battery Power Efficiency (Business Wire) +5.36%
Apr-09-26 04:01PM	Magnachip to Announce First Quarter 2026 Financial Results on April 28, 2026 (Business Wire)
06:55AM	Loading…
Mar-30-26 06:55AM	Magnachip Launches 8th-Generation 40V and 60V MV MOSFETs for Servers and High-Performance PCs (Business Wire) -5.92%
Mar-05-26 12:01AM	MagnaChip Semiconductor Corp (MX) Q4 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +7.09%
Mar-04-26 11:36PM	1 of Wall Street's Favorite Stock to Keep an Eye On and 2 We Brush Off (StockStory)
08:48PM	Magnachip Semiconductor Q4 Earnings Call Highlights (MarketBeat)
05:15PM	Magnachip (MX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
05:00PM	No Surprises In Magnachip's (NYSE:MX) Q4 Sales Numbers, Stock Soars (StockStory)
04:21PM	Magnachip: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Magnachip Reports Results for Fourth Quarter and Full-Year 2025 (Business Wire)
Mar-03-26 05:06AM	Magnachip Earnings: What To Look For From MX (StockStory)
Feb-26-26 06:55AM	Magnachip Launches New 24V BatteryFET for Tri-Fold Smartphone Battery Protection (Business Wire) +6.34%
Feb-17-26 05:35PM	Pitney Bowes (PBI) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-15-26 11:44PM	3 Volatile Stocks We Keep Off Our Radar (StockStory)
Feb-11-26 11:34PM	1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky (StockStory)
11:04PM	3 Reasons MX is Risky and 1 Stock to Buy Instead (StockStory)
04:01PM	Magnachip to Announce Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
02:55PM	Loading…
Jan-23-26 02:55PM	Magnachip, Vishay Intertechnology, Power Integrations, onsemi, and Allegro MicroSystems Stocks Trade Down, What You Need To Know (StockStory)
Jan-21-26 11:35PM	3 Cash-Burning Stocks with Questionable Fundamentals (StockStory)
Jan-20-26 06:55AM	Magnachip Targets Solar and Energy Storage Systems Markets with New Generation of High-Efficiency IGBT Series (Business Wire)
06:30AM	Magnachip Announces the Appointment of Cristiano Amoruso to Its Board of Directors (Business Wire)
Jan-14-26 06:30AM	Magnachip Announces the Retirement of Director Ilbok Lee (Business Wire)
Jan-12-26 11:37PM	3 of Wall Street's Favorite Stocks Walking a Fine Line (StockStory)
Dec-31-25 10:32PM	Reflecting On Analog Semiconductors Stocks' Q3 Earnings: Magnachip (NYSE:MX) (StockStory) +5.10%
Nov-20-25 01:27AM	Magnachip Finalizes IGBT Technology Agreement with Hyundai Mobis (Insider Monkey)
Nov-12-25 11:31PM	1 Small-Cap Stock to Own for Decades and 2 We Find Risky (StockStory)
Nov-10-25 11:36PM	3 Cash-Burning Stocks with Questionable Fundamentals (StockStory)
12:33AM	Magnachip's Q3 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Nov-05-25 12:27PM	Why Magnachip (MX) Stock Is Trading Lower Today (StockStory) -10.18%
Nov-04-25 01:30PM	Why Magnachip (MX) Shares Are Sliding Today (StockStory) -8.36%
08:41AM	MX Q3 Deep Dive: Management Outlines Turnaround Amid Challenging Market and Weak Guidance (StockStory)
12:04AM	MagnaChip Semiconductor Corp (MX) Q3 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Nov-03-25 06:00PM	Magnachip (MX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:03PM	Magnachip: Q3 Earnings Snapshot (Associated Press Finance)
04:43PM	Magnachip (NYSE:MX) Reports Q3 In Line With Expectations (StockStory)
04:10PM	Magnachip to Expand Its Industrial IGBT Business Based on Advanced Traction Inverter IGBT Technology Jointly Developed in Strategic Partnership with Hyundai Mobis (Business Wire)
04:05PM	Magnachip Reports Results for Third Quarter 2025 (Business Wire)
Nov-01-25 11:10PM	Magnachip Earnings: What To Look For From MX (StockStory)
Oct-31-25 02:47PM	Will These 4 Semiconductor Stocks Beat Forecasts in Q3 Earnings? (Zacks)
09:34AM	MagnaChip Semiconductor Corp (MX) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-29-25 06:55AM	Magnachip Launches 650V Super Junction TOLL Package Products with Integrated Kelvin Source (Business Wire)
Oct-27-25 12:03AM	3 Reasons MX is Risky and 1 Stock to Buy Instead (StockStory)
Oct-23-25 05:40PM	MaxLinear (MXL) Q3 Earnings and Revenues Beat Estimates (Zacks)
Oct-21-25 04:05PM	Magnachip to Announce Third Quarter 2025 Financial Results on November 3, 2025 (Business Wire)
Oct-10-25 12:20PM	Why Magnachip (MX) Stock Is Falling Today (StockStory)
Oct-08-25 12:34AM	3 Cash-Heavy Stocks We Think Twice About (StockStory)
Oct-07-25 02:00PM	Magnachip, Analog Devices, and onsemi Stocks Trade Down, What You Need To Know (StockStory)
Oct-03-25 12:33AM	3 of Wall Street's Favorite Stocks We Approach with Caution (StockStory)
Sep-30-25 12:41AM	3 Unprofitable Stocks We Approach with Caution (StockStory)
Sep-16-25 11:37PM	Spotting Winners: Magnachip (NYSE:MX) And Analog Semiconductors Stocks In Q2 (StockStory)
Sep-05-25 04:47PM	Semi Stocks ADI and MX Grow Despite Tariffs and Geopolitics (Zacks)
Aug-25-25 12:37AM	3 Out-of-Favor Stocks We Think Twice About (StockStory)
Aug-21-25 12:34AM	3 Volatile Stocks That Concern Us (StockStory)
Aug-18-25 12:46AM	1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm (StockStory)
Aug-13-25 04:05PM	Magnachip, AMD, NXP Semiconductors, onsemi, and Qorvo Stocks Trade Up, What You Need To Know (StockStory)
12:32AM	3 Small-Cap Stocks That Concern Us (StockStory)
Aug-12-25 11:03PM	5 Insightful Analyst Questions From Magnachip's Q2 Earnings Call (StockStory) +9.33%
10:56PM	MX Q2 Deep Dive: Guidance Cut and Pricing Pressures Dominate, New Product Pipeline Critical (StockStory)
03:50PM	Magnachip, Intel, Microchip Technology, NXP Semiconductors, and onsemi Shares Skyrocket, What You Need To Know (StockStory)
Aug-11-25 04:15PM	Magnachip Semiconductor Announces YJ Kim to Step Down as CEO; Current Board Chairman Camillo Martino Appointed Interim CEO (Business Wire)
Aug-08-25 03:39PM	3 of Wall Street's Favorite Stocks We Steer Clear Of (StockStory)
Aug-01-25 12:20PM	Why Magnachip (MX) Stock Is Trading Lower Today (StockStory) -27.80%
Jul-31-25 05:35PM	Magnachip (MX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:02PM	Magnachip (NYSE:MX) Posts Better-Than-Expected Sales In Q2 But Stock Drops 11.6% (StockStory)
04:32PM	Magnachip: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Magnachip Reports Results for Second Quarter 2025 (Business Wire)
Jul-30-25 10:04AM	MagnaChip Semiconductor Corp (MX) Q2 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
Jul-29-25 11:19PM	Magnachip (MX) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
Jul-28-25 12:15PM	Magnachip (MX) Stock Trades Up, Here Is Why (StockStory)
06:55AM	Magnachip Introduces TOLT-Packaged 80V MXT MV MOSFET for E-Scooters and LEVs (Business Wire)
Jul-23-25 12:33AM	1 Momentum Stock to Target This Week and 2 We Find Risky (StockStory)
12:01AM	3 Reasons to Avoid MX and 1 Stock to Buy Instead (StockStory)
Jul-10-25 04:05PM	Magnachip to Announce Second Quarter 2025 Financial Results on July 31, 2025 (Business Wire)
Jul-07-25 03:40PM	Why Magnachip (MX) Stock Is Down Today (StockStory)
Jun-13-25 09:57AM	Magnachip to Participate in the 15th Annual ROTH London Conference (Business Wire)
Jun-11-25 11:30PM	Q1 Earnings Outperformers: Magnachip (NYSE:MX) And The Rest Of The Analog Semiconductors Stocks (StockStory)
Jun-09-25 12:32AM	1 Small-Cap Stock to Research Further and 2 to Question (StockStory)
Jun-04-25 04:05PM	Magnachip Provides Update on Board Corporate Governance Initiative (Business Wire)
10:11AM	MX Q1 Earnings Call: Display Exit, Power Segment Focus, and Margin Expansion Initiatives (StockStory)
May-26-25 12:19PM	ON Semiconductor Plunges 35% YTD: Buy, Sell or Hold the Stock? (Zacks)
12:39AM	3 Cash-Burning Stocks with Questionable Fundamentals (StockStory)
May-23-25 12:41AM	1 Surging Stock with Exciting Potential and 2 to Avoid (StockStory) -5.88%
May-16-25 01:52PM	NXP Rises 23% in a Month: Should Investors Hold on to the Stock? (Zacks)
May-13-25 03:11AM	MagnaChip Semiconductor Corp (MX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-12-25 05:20PM	Magnachip (MX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Magnachip: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Magnachip Reports Results for First Quarter 2025 (Business Wire)

Magnachip Semiconductor Corp. engages in the design and manufacture of analog and mixed-signal platform solutions for communications, Internet of Things (IoT), consumer, computing, industrial, and automotive applications. Its products include MOSFETs, IGBTs, AC-DC/DC-DC converters, light-emitting diode (LED) drivers, regulators, power management integrated circuits (PMICs), and industrial applications such as power suppliers, e-bikes, photovoltaic inverters, LED lighting, and motor drives. The company was founded on November 26, 2003 and is headquartered in Cheongju-si, South Korea.

CFOMs. Shin Young Park

Act. Co-GM of Power Analog Sol.Mr. Seung-Hoon Lee

CEO & DirectorMr. Chae Lee

Chief of Strategic PlanningMr. Jk Minh

CTO of PAS GroupMr. Hyuk Woo

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEE CHAE	Chief Executive Officer	Sep 23 '26	Buy	3.18	80,000	254,098	368,750	Sep 25 04:15 PM
LEE CHAE	Chief Executive Officer	Sep 24 '26	Buy	3.22	20,000	64,398	388,750	Sep 25 04:15 PM
NATHAN GILBERT E	Director	Mar 16 '26	Buy	2.87	21,994	63,050	158,200	Mar 17 04:30 PM
NATHAN GILBERT E	Director	Mar 12 '26	Buy	2.75	25,000	68,675	123,200	Mar 16 04:30 PM
NATHAN GILBERT E	Director	Mar 13 '26	Buy	2.79	13,006	36,249	136,206	Mar 16 04:30 PM

Open in Screener

URG

Ur-Energy Inc

1.13

Sep 25 • 3:59 PM ET 0.00 (0.00%)

1.17

Aftermarket • 7:58 PM ET +0.04 (3.54%)

Energy Uranium USA Small AMEX

Peers: ISOU DNN UUUU UEC NXE CCJ NNE SMR BWXT OKLO

| Held by: URNM NLR URA XME VTI URNJ IWM VXF IWO VTWO

Index	RUT
Market Cap	449.59M
Enterprise Value	425.21M
Income	-88.51M
Sales	35.08M
Book/sh	0.17
Cash/sh	0.24
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	157
IPO	Jan 19, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	12.82
P/B	6.52
P/C	4.70
P/FCF	-
EV/EBITDA	-
EV/Sales	12.12
Quick Ratio	3.25
Current Ratio	4.00
Debt/Eq	1.03
LT Debt/Eq	1.02
Option/Short	No / Yes

EPS (ttm)	-0.23
EPS next Y	-0.03
EPS next Q	-0.04
EPS this Y	18.00%
EPS next Y	81.71%
EPS next 5Y	-
EPS past 3/5Y	-37.80% -17.70%
Sales past 3/5Y	1027.13% 26.75%
EPS Y/Y TTM	-39.84%
Sales Y/Y TTM	-11.17%
EPS Q/Q	26.83%
Sales Q/Q	37.74%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	-49.81% 0.08%

Insider Own	8.02%
Insider Trans	-1.25%
Inst Own	84.59%
Inst Trans	5.10%
ROA	-40.05%
ROE	-103.50%
ROIC	-63.41%
Gross Margin	-186.48%
Oper. Margin	-218.24%
Profit Margin	-252.34%
SMA20	-11.96%
SMA50	-13.82%
SMA200	-25.33%
Trades

Shs Outstand	397.77M
Shs Float	365.97M
Short Float	15.72%
Short Ratio	7.72
Short Interest	57.53M
52W High	2.35 -51.91%
52W Low	1.12 0.89%
Volatility	4.71% 4.46%
ATR (14)	0.06
RSI (14)	32.15
Beta	1.14
Rel Volume	0.64
Avg Volume	7.45M
Volume	4,802,795

Perf Week	-5.04%
Perf Month	-25.66%
Perf Quarter	-16.30%
Perf Half Y	-20.42%
Perf YTD	-18.71%
Perf Year	-35.43%
Perf 3Y	-31.52%
Perf 5Y	-31.10%
Perf 10Y	125.77%
Recom	1.00
Target Price	2.18
Prev Close	1.13
Price	1.13
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-26	Initiated	RBC Capital Mkts	Outperform	$1.75
Apr-02-26	Initiated	Canaccord Genuity	Buy
Oct-27-25	Initiated	Northland Capital	Outperform	$2.15
Jul-25-25	Initiated	Maxim Group	Buy	$3
Jul-23-25	Resumed	B. Riley Securities	Buy	$2
Feb-02-24	Initiated	B. Riley Securities	Buy	$3
Sep-02-16	Initiated	FBR Capital	Outperform	$1
Jun-19-15	Resumed	H.C. Wainwright	Buy	$2.10
Aug-10-11	Initiated	Rodman & Renshaw	Mkt Outperform	$2.52
Dec-30-10	Reiterated	Rodman & Renshaw	Mkt Outperform	$3 → $4.25

Aug-24-26 05:23PM	Uranium Energy Stock Is Priced On Pounds It Has Not Sold Yet (Trefis)
Aug-20-26 06:50AM	Ur-Energy Announces First Shipment of Uranium from Shirley Basin Mine, Wyoming (ACCESSWIRE)
Aug-11-26 07:01PM	Ur-Energy Inc (URG) (Q2 2026) Earnings Call Highlights: Production Surges 47% as Shirley Basin ... (GuruFocus.com)
08:30AM	Ur-Energy Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-10-26 05:25PM	Ur-Energy Reports Second Quarter 2026 Results (ACCESSWIRE)
05:10PM	Loading…
Aug-05-26 05:10PM	Ur-Energy Announces Date for Second Quarter 2026 Results and Conference Call and Webcast (ACCESSWIRE)
Aug-04-26 09:00AM	Eagle Nuclear Energy Corp. Holds the Rights to the Largest conventional, measured and indicated uranium Deposit in the USA, and It's Systematically Advancing It Toward Development (PR Newswire)
Jul-29-26 08:31AM	The Next AI Trade: Fireside Chat with Noble Plains Uranium CEO Drew Zimmerman (IPO-Edge.com)
Jul-14-26 07:45PM	Ur-Energy Appoints US Energy and Mining Veteran as Chair of the Board (ACCESSWIRE)
Jul-09-26 08:48AM	Noble Plains Uranium Completes Shirley Central Historical Drill Database, Unlocking 341 Uranium Intercepts (TMX Newsfile)
Jun-29-26 07:00AM	Ur-Energy Receives Final WDEQ Authorization to Transport Uranium-Loaded Resin from Shirley Basin to Lost Creek (ACCESSWIRE)
Jun-25-26 04:10PM	Noble Plains Closes $1,009,600 Non-Brokered Private Placement (TMX Newsfile)
Jun-23-26 09:34PM	American Rare Earths strengthens board with veteran Wyoming mine builder ahead of planned Nasdaq listing (Proactive)
Jun-17-26 07:00AM	Ur-Energy Celebrates 100th Shipment of Yellowcake from Lost Creek ISR Uranium Mine, Wyoming (ACCESSWIRE) -5.49%
Jun-05-26 07:00AM	Ur-Energy Reports Results of Annual General and Special Meeting of Shareholders (ACCESSWIRE) -16.06%
08:04AM	Loading…
Jun-03-26 08:04AM	Nuclear Stocks Jump on Multibillion-Dollar Uranium Growth Project (GuruFocus.com) -8.10%
May-12-26 03:05AM	Ur-Energy Inc (URG) Q1 2026 Earnings Call Highlights: Strong Production Growth and Strategic ... (GuruFocus.com) +6.59%
May-11-26 08:00AM	Ur-Energy Reminds Shareholders and Interested Parties of First Quarter Conference Call and Webcast (ACCESSWIRE)
May-08-26 06:48AM	Ur-Energy Reports Q1 2026 Results and Announces Conference Call and Webcast (ACCESSWIRE)
Apr-23-26 07:00AM	Ur-Energy Commences Operations at its Shirley Basin ISR Project, Wyoming, Advancing U.S. Uranium Production (ACCESSWIRE)
Apr-15-26 08:30AM	Noble Plains Uranium Announces Strategic Letter of Intent with Ur-Energy for Potential Processing of Shirley Central Uranium Production (Newsfile)
Mar-11-26 09:05PM	Ur-Energy Inc (URG) Q4 2025 Earnings Call Highlights: Strong Inventory Growth and Strategic ... (GuruFocus.com)
04:44PM	Ur-Energy Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-10-26 07:00PM	Ur Energy (URG) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +6.94%
05:40PM	Ur-Energy Updates Lost Creek Property Technical Report Summary Estimating an Extended Mine Life and Increase in Net Cash Flow (ACCESSWIRE)
05:30PM	Ur-Energy Reports Year-End 2025 Results and Announces Conference Call and Webcast (ACCESSWIRE)
Feb-18-26 11:51AM	Cameco Delivers Earnings Beat in Q4: Here's How to Play the Stock (Zacks)
Feb-06-26 11:17AM	Ur-Energy (URG) Provides Update on Two Uranium Exploration Projects (Insider Monkey)
Feb-03-26 08:00AM	Noble Plains Uranium Completes Agreement to Acquire Drill Data on Shirley Central Project in Wyoming (Newsfile)
Jan-28-26 07:00AM	Ur-Energy Advances Growth Portfolio in the Great Divide Basin (ACCESSWIRE)
02:10PM	Loading…
Jan-21-26 02:10PM	Trump Champions Atomic Energy At Davos-Nuclear Stocks Climb (Benzinga)
Jan-15-26 09:39AM	ETFs Primed to Benefit From America's $2.7 Billion Nuclear Push (Zacks)
Dec-29-25 12:54PM	Energy Fuels' 2025 Production Tops Expectations: More Upside Ahead? (Zacks)
Dec-23-25 12:29AM	Analyst Initiates Coverage of Ur-Energy (URG) with a 'Buy' Rating, $2 Price Target (Insider Monkey)
Dec-18-25 07:30AM	Noble Plains Uranium Acquires Historical Drill Data For 1,211 Holes On Shirley Central Project in Wyoming (Newsfile)
Dec-15-25 05:05PM	Ur-Energy Announces Closing of US$120 Million Offering of 4.75% Convertible Senior Notes Due 2031, Including Full Exercise of Initial Purchasers' Option to Purchase Additional Notes (ACCESSWIRE)
Dec-12-25 12:24PM	Is CCJ Prepared to Offset McArthur River Losses With Cigar Lake Gains? (Zacks)
Dec-11-25 01:20AM	Ur-Energy Announces Pricing of $100 Million Offering of 4.75% Convertible Senior Notes Due 2031 (ACCESSWIRE) -8.09%
Dec-10-25 04:05PM	Ur-Energy Announces Proposed $100 Million Offering of Convertible Senior Notes Due 2031 (ACCESSWIRE)
Nov-25-25 07:57AM	Ur-Energy Announces Retirement of General Counsel and Corporate Secretary Penne Goplerud and Names Alex Ritchie as Successor (ACCESSWIRE)
Nov-24-25 09:47AM	Maxim Group Affirms Buy Rating on Ur-Energy Inc. (URG) on Growing Uranium Demand Opportunity (Insider Monkey) +8.55%
Nov-11-25 09:45PM	Ur-Energy (URG) Misses Expectations in Q3 (Insider Monkey)
Nov-07-25 12:59PM	Should Investors Bet on Cameco Stock Post the Q3 Earnings Miss? (Zacks)
Nov-06-25 12:08PM	Should You Buy, Hold or Sell UUUU Stock Post Q3 Earnings? (Zacks) -7.30%
Nov-05-25 12:43PM	USA Rare Earth is Set to Report Q3 Earnings: Here's What to Expect (Zacks)
Nov-03-25 07:40PM	Ur Energy (URG) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.40% -10.56%
05:35PM	Ur-Energy Announces Q3 2025 Results; Construction Advances at Shirley Basin and Exploration Underway in the Great Divide Basin (ACCESSWIRE)
Oct-31-25 01:11PM	Energy Fuels Set to Report Q3 Earnings: Buy, Sell or Hold the Stock? (Zacks)
Oct-30-25 10:00AM	MP Materials Corp. (MP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-29-25 10:00AM	Earnings Preview: Ur Energy (URG) Q3 Earnings Expected to Decline (Zacks)
Oct-16-25 07:00AM	Ur-Energy Participates in the 2025 Maxim Growth Summit in New York (ACCESSWIRE) -13.79%
Oct-13-25 06:40AM	Ur-Energy Announces Retirement of CEO John Cash, Names President Matthew Gili as Successor (ACCESSWIRE)
Oct-08-25 10:13AM	Cameco Rallies 116% in 6 Months: How to Play the Stock? (Zacks)
Oct-07-25 11:13AM	Is Uranium Energy Timing Its Sales for Maximum Market Advantage? (Zacks)
07:00AM	Ur-Energy Participates in TD Cowen's 10th Annual Nuclear Fuel Cycle and Next Generation Nuclear Roundtable (ACCESSWIRE)
Sep-29-25 06:09AM	Can Energy Fuels Capitalize on the Recent Gain in Uranium Prices? (Zacks)
Sep-24-25 11:29AM	CCJ vs. URG: Which Uranium Stock is the Better Buy Today? (Zacks)
Sep-23-25 07:00AM	Ur-Energy Welcomes Mr. Jade Walle as Vice President Finance (ACCESSWIRE)
Sep-18-25 05:00AM	Nuclear power could be a $10 trillion industry that 'holds the answer to the world's power shortages' (Yahoo Finance)
Sep-12-25 10:58AM	H.C. Wainwright Reaffirms 'Buy' Rating on Ur-Energy Inc. (URG) With a $2.70 Price Target (Insider Monkey)
Sep-03-25 05:15PM	Ur-Energy Presents at the 27th Annual H.C. Wainwright Global Investment Conference, September 8-10, 2025 (ACCESSWIRE) +13.87%
09:56AM	UUUU Ramps Up Uranium Output & Sets Bold 2025 Targets: What's Next? (Zacks)
Sep-01-25 10:58AM	CCJ Cuts McArthur Rive Output Outlook: Can Cigar Lake Bridge the Gap? (Zacks)
Aug-24-25 12:53AM	H.C. Wainwright Reiterates Buy Rating on Ur-Energy (URG) (Insider Monkey)
Aug-12-25 01:25PM	Cameco Posts Q2 Earning Beat: A Compelling Reason to Buy the Stock? (Zacks)
Aug-08-25 11:52AM	Should You Buy, Hold or Sell UUUU Stock Post Q2 Earnings? (Zacks)
Aug-05-25 11:31AM	Energy Fuels Set to Report Q2 Earnings: Buy, Sell or Hold the Stock? (Zacks)
08:05AM	Ur Energy (URG) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Ur-Energy Reports Q2 2025 and Announces Eighth Uranium Sales Agreement (ACCESSWIRE)
Aug-01-25 10:00AM	Will Ur Energy (URG) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-31-25 11:36AM	Cameco Posts Strong Q2 Revenue Gains: Will Momentum Last Through 2025? (Zacks)
Jul-25-25 09:55AM	Should You Buy Ur Energy (URG) After Golden Cross? (Zacks)
08:35AM	Metals & Mining Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Jul-22-25 11:24AM	Can Cameco Sustain Its Strong Revenue Growth Through 2025? (Zacks)
08:35AM	Metals & Mining Virtual Investor Conference Agenda Announced for July 23rd and 24th (GlobeNewswire)
Jul-15-25 07:00AM	Ur-Energy Provides Operational and Construction Updates for Q2 2025 (ACCESSWIRE) +9.32%
Jul-14-25 12:25PM	Cameco Gains 41.5% YTD: Should You Buy, Sell or Hold the Stock? (Zacks)
Jul-11-25 11:33AM	Can Cameco Deliver on Its Uranium Production Targets for 2025? (Zacks)
Jul-09-25 10:05AM	Can Centrus Energy Scale Fast Enough to Meet Surging HALEU Demand? (Zacks)
Jul-07-25 09:02AM	Can Pinyon Plain Mine Drive Energy Fuels' Next Phase of Growth? (Zacks)
Jun-30-25 07:50AM	Ur-Energy Announces Appointment of Matthew Gili as President as Ur-Energy Advances Wyoming Uranium Production (ACCESSWIRE)
Jun-20-25 06:24AM	Ur-Energy (URG) Gains Amid Bullish Outlook on Uranium (Insider Monkey) -9.73%
Jun-16-25 07:00AM	Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream (GlobeNewswire) +14.65%
Jun-13-25 09:03AM	Ur-Energy to Present June 17 at the Emerging Growth Conference (ACCESSWIRE)
Jun-06-25 05:05PM	Ur-Energy Reports Results of Annual General and Special Meeting of Shareholders (ACCESSWIRE) +16.82%
Jun-04-25 12:06PM	How Energy Fuels Gears Up to Revitalize the US Nuclear Energy Sector (Zacks)
May-27-25 08:20AM	Ur-Energy Commends President Trump's Bold Executive Orders for the Reinvigoration of the U.S. Nuclear Industry and U.S. Energy Security (ACCESSWIRE) +6.90%
May-08-25 06:14PM	Ur Energy: Q1 Earnings Snapshot (Associated Press Finance)
05:20PM	Ur-Energy Releases 2025 Q1 Results and Announces Receipt of Final Approval for Lost Creek Expansion (ACCESSWIRE)
Apr-28-25 05:05PM	Ur-Energy Receives State Approval for the LC East HJ and KM Permit to Mine Amendments (ACCESSWIRE)
Apr-25-25 10:56AM	Why Ur-Energy Inc. (URG) Stock is Rising This Week (Insider Monkey)
Apr-23-25 12:45PM	Ur-Energy Inc. (URG): The Best Uranium Stock to Invest in According to Analysts (Insider Monkey)
Apr-18-25 09:40AM	Why Ur-Energy Inc. (URG) Stock is Gaining This Week (Insider Monkey)
Apr-15-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire) -6.30%
Mar-31-25 07:03PM	UR-ENERGY ANNOUNCES DELAY FILING YEAR-END REPORTING DOCUMENTS (PR Newswire)
Feb-10-25 05:05PM	Ur-Energy Provides Production and Construction Updates Including its Leadership Position as a Strategic Producer of US Uranium (ACCESS Newswire)
Jan-15-25 01:30PM	Maxim Group LLC to Host the 2025 Mining Conference: Mining & Supplying Critical Minerals & Precious Metals on Thursday, January 16th at 9:00 a.m. E.T. (GlobeNewswire)
Jan-09-25 02:02PM	Ur-Energy Will Participate in the "2025 Mining Conference: Mining & Supplying Critical Minerals & Precious Metals" Presented by Maxim Group LLC on Thursday, January 16 (ACCESSWIRE)
Jan-08-25 02:47PM	Is Ur-Energy Inc. (URG) the Best Uranium Stock to Invest In Now? (Insider Monkey)
Nov-06-24 07:30PM	Ur Energy (URG) Reports Q3 Loss, Lags Revenue Estimates (Zacks)

Ur-Energy, Inc. engages in the business of uranium mining, recovery, and processing activities including the acquisition, exploration, development, and operation of uranium mineral properties. Its projects include Lost Creek, Shirley Basin, Lost Soldier, Lucky Mc Mine Site, and Excel Gold properties. The company was founded by Jeffrey T. Klenda and Paul W. Pitman on March 22, 2004 and is headquartered in Casper, WY.

P.Eng.Mr. Matthew D. Gili B.Sc.

CGMAMr. Roger L. Smith CPA

Chief Operating OfficerMr. Steven M. Hatten B.Sc.

Director & Strategic and Technical AdvisorMr. John W. Cash M.Sc.

Director of Investor RelationsMs. Valerie K. Kimball

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Walle Jade	VICE PRESIDENT FINANCE	Sep 24 '26	Buy	1.14	96,556	110,071	424,037	Sep 25 04:35 PM
Walle Jade	VICE PRESIDENT FINANCE	Sep 11 '26	Buy	1.29	75,581	97,499	327,481	Sep 15 08:46 AM
Parker Thomas H	Director	Aug 25 '26	Option Exercise	1.04	87,858	91,416	668,742	Aug 26 05:11 PM
Parker Thomas H	Director	Aug 25 '26	Sale	1.48	87,858	130,276	580,884	Aug 26 05:11 PM
HUBER GARY C	Director	Aug 25 '26	Option Exercise	1.04	87,858	91,416	645,874	Aug 26 05:07 PM
HUBER GARY C	Director	Aug 25 '26	Sale	1.48	87,858	129,942	558,016	Aug 26 05:07 PM
RITCHIE DAVID A.	GENERAL COUNSEL/CORP SECRETARY	Aug 24 '26	Buy	1.42	10,000	14,200	10,000	Aug 25 05:09 PM
CASH JOHN	Director	Aug 24 '26	Option Exercise	1.04	77,751	80,884	774,015	Aug 25 05:09 PM
CASH JOHN	Director	Aug 24 '26	Sale	1.41	77,751	109,652	696,264	Aug 25 05:09 PM
Chang Robby Sai Kit	Director	Aug 24 '26	Option Exercise	1.04	87,858	91,399	172,037	Aug 25 05:08 PM
Chang Robby Sai Kit	Director	Aug 24 '26	Sale	1.41	75,588	106,503	96,449	Aug 25 05:08 PM
SMITH ROGER L.	CHIEF FINANCIAL OFFICER	Aug 24 '26	Option Exercise	1.04	103,536	107,709	755,098	Aug 25 05:08 PM
SMITH ROGER L.	CHIEF FINANCIAL OFFICER	Aug 24 '26	Sale	1.43	103,536	148,284	651,562	Aug 25 05:08 PM
WALKER KATHY E	Director	Aug 21 '26	Option Exercise	1.05	87,858	91,935	660,105	Aug 24 05:07 PM
WALKER KATHY E	Director	Aug 21 '26	Sale	1.38	72,838	100,546	587,267	Aug 24 05:07 PM
HATTEN STEVEN M.	Chief Operating Officer	Aug 21 '26	Option Exercise	1.05	81,576	85,361	427,340	Aug 24 05:05 PM
HATTEN STEVEN M.	Chief Operating Officer	Aug 21 '26	Sale	1.39	81,576	113,227	345,764	Aug 24 05:05 PM
Walle Jade	VICE PRESIDENT FINANCE	Mar 18 '26	Buy	1.39	107,900	149,981	251,900	Mar 19 05:05 PM
GOPLERUD PENNE A	Gen Counsel and Corp Secretary	Dec 23 '25	Option Exercise	1.47	17,966	26,333	448,574	Dec 29 06:13 PM
HUBER GARY C	Director	Dec 23 '25	Option Exercise	1.47	16,407	24,048	558,016	Dec 29 06:12 PM
Parker Thomas H	Director	Dec 23 '25	Option Exercise	1.47	16,407	24,048	580,884	Dec 29 06:11 PM
WALKER KATHY E	Director	Dec 23 '25	Option Exercise	1.47	16,407	24,048	572,247	Dec 29 06:10 PM
HATTEN STEVEN M.	Chief Operating Officer	Dec 23 '25	Option Exercise	1.47	20,989	30,764	345,764	Dec 29 06:08 PM
SMITH ROGER L.	CHIEF FINANCIAL OFFICER	Dec 23 '25	Option Exercise	1.47	19,387	28,416	651,562	Dec 29 06:04 PM
CASH JOHN	Director	Dec 23 '25	Option Exercise	1.47	35,296	51,733	696,264	Dec 29 06:03 PM
Chang Robby Sai Kit	Director	Dec 24 '25	Option Exercise	1.45	16,407	23,869	100,586	Dec 29 06:00 PM
Walle Jade	VICE PRESIDENT FINANCE	Nov 20 '25	Buy	1.27	144,000	182,880	144,000	Nov 21 05:06 PM
Gili Matthew David	PRESIDENT	Nov 14 '25	Buy	1.21	155,000	187,550	155,000	Nov 17 05:08 PM
HUBER GARY C	Director	Nov 12 '25	Option Exercise	0.45	163,914	73,729	591,609	Nov 13 05:24 PM
HUBER GARY C	Director	Nov 12 '25	Sale	1.29	50,000	64,625	541,609	Nov 13 05:24 PM
CASH JOHN	Board Chairman, CEO	Nov 11 '25	Option Exercise	0.45	189,303	85,073	850,271	Nov 12 05:28 PM
CASH JOHN	Board Chairman, CEO	Nov 11 '25	Sale	1.27	189,303	240,207	660,968	Nov 12 05:28 PM
GOPLERUD PENNE A	Gen Counsel and Corp Secretary	Nov 10 '25	Option Exercise	0.45	226,630	101,848	657,238	Nov 12 05:24 PM
GOPLERUD PENNE A	Gen Counsel and Corp Secretary	Nov 10 '25	Sale	1.29	226,630	291,922	430,608	Nov 12 05:24 PM
HUBER GARY C	Director	Nov 10 '25	Option Exercise	0.45	50,000	22,470	477,695	Nov 12 05:18 PM
HUBER GARY C	Director	Nov 10 '25	Sale	1.29	50,000	64,410	427,695	Nov 12 05:18 PM
WALKER KATHY E	Director	Nov 06 '25	Option Exercise	0.45	213,914	95,470	630,567	Nov 07 05:10 PM
WALKER KATHY E	Director	Nov 06 '25	Sale	1.32	74,727	98,632	555,840	Nov 07 05:10 PM
Parker Thomas H	Director	Nov 06 '25	Option Exercise	0.45	213,914	95,470	564,477	Nov 07 05:07 PM

Open in Screener

ANNX

Annexon Inc

3.64

Sep 25 • 3:59 PM ET -0.16 (-4.21%)

3.84

Aftermarket • 7:58 PM ET +0.20 (5.49%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR RYTM INCY BMRN CRNX VKTX KRYS AXSM MDGL NBIX

| Held by: VTI XBI IWM VXF IWO IBB VTWO FESM SCHA IWC

Index	RUT
Market Cap	690.07M
Enterprise Value	505.48M
Income	-202.67M
Sales	0.00M
Book/sh	1.07
Cash/sh	1.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	96
IPO	Jul 24, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.42
P/C	3.30
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.53
Current Ratio	5.53
Debt/Eq	0.13
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	-1.15
EPS next Y	-0.99
EPS next Q	-0.28
EPS this Y	21.71%
EPS next Y	5.29%
EPS next 5Y	43.63%
EPS past 3/5Y	19.69% 20.17%
Sales past 3/5Y	- -
EPS Y/Y TTM	10.96%
Sales Y/Y TTM	-
EPS Q/Q	19.92%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-17.25% -

Insider Own	12.98%
Insider Trans	2.74%
Inst Own	89.45%
Inst Trans	15.51%
ROA	-79.38%
ROE	-105.26%
ROIC	-97.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.81%
SMA50	-25.56%
SMA200	-32.30%
Trades

Shs Outstand	174.60M
Shs Float	164.97M
Short Float	19.93%
Short Ratio	9.39
Short Interest	32.87M
52W High	7.18 -49.30%
52W Low	2.54 43.31%
Volatility	5.82% 5.40%
ATR (14)	0.25
RSI (14)	26.37
Beta	1.33
Rel Volume	1.00
Avg Volume	3.50M
Volume	3,511,268

Perf Week	-13.95%
Perf Month	-27.05%
Perf Quarter	-33.58%
Perf Half Y	-30.67%
Perf YTD	-27.49%
Perf Year	30.47%
Perf 3Y	46.18%
Perf 5Y	-82.63%
Perf 10Y	-
Recom	1.36
Target Price	15.50
Prev Close	3.80
Price	3.64
Change %	-4.21%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-26	Upgrade	Citizens	Mkt Underperform → Mkt Perform
Jul-21-26	Initiated	Citizens	Mkt Underperform	$3
May-12-26	Initiated	Goldman	Neutral	$7
Dec-23-25	Initiated	Chardan Capital Markets	Buy	$16
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Sep-24-26 08:00AM	Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting (GlobeNewswire)
Sep-16-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Sep-02-26 08:00AM	Annexon to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-17-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-26 04:56PM	Annexon, Inc. Q2 2026 Earnings Call Summary (Moby)
07:33AM	Loading…
07:33AM	Annexon shares fall as second-quarter loss exceeds Wall Street forecasts (InvestorsHub)
06:05AM	Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones (GlobeNewswire)
06:00AM	Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study (GlobeNewswire)
Aug-10-26 04:05PM	Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors (GlobeNewswire)
Aug-06-26 08:00AM	Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week (GlobeNewswire)
Jul-30-26 04:01PM	Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance (GlobeNewswire) +8.44%
Jul-16-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.38%
Jul-14-26 04:05PM	Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 (GlobeNewswire) +17.12%
Jun-16-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.29%
May-27-26 08:00AM	Annexon to Participate in Upcoming June Investor Conferences (GlobeNewswire)
04:05PM	Loading…
May-18-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-26 04:01PM	Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire)
May-06-26 08:00AM	Annexon to Present at the Bank of America Securities Health Care Conference 2026 (GlobeNewswire)
Apr-08-26 04:05PM	Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-26 08:00PM	Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High? (Quartz)
Mar-30-26 04:01PM	Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +11.69%
Mar-16-26 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 05:48AM	Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference (MarketBeat)
Feb-24-26 08:00AM	Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-17-26 08:00AM	Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy (GlobeNewswire)
Jan-16-26 05:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-26 05:10PM	Annexon Maps Pivotal 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead (MarketBeat) +7.92% -7.78%
Jan-12-26 07:00AM	Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 (GlobeNewswire) +5.90%
Jan-08-26 08:00AM	Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barre Syndrome (GlobeNewswire)
Jan-07-26 04:05PM	Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.43%
08:13AM	Loading…
Dec-23-25 08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-18-25 01:14AM	Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development (Insider Monkey)
Dec-16-25 07:31PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-25 01:26AM	Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement (Insider Monkey)
Nov-14-25 04:01PM	Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million (GlobeNewswire) +11.44%
Nov-12-25 10:55PM	Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.63%
04:12PM	Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-10-25 04:05PM	Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire)
Sep-30-25 11:41AM	Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition (Insider Monkey)
Aug-27-25 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.81%
Aug-14-25 04:05PM	Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -8.46%
Aug-11-25 07:29AM	Annexon announces EMA selection of vonaprument for PDC pilot participation (Pharmaceutical Business Review)
Aug-07-25 04:30PM	Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy (GlobeNewswire)
Jul-24-25 07:00AM	Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
Jun-18-25 04:05PM	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) (GlobeNewswire)
May-29-25 04:05PM	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.39% -6.42%
May-19-25 04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-16-25 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
May-12-25 08:00AM	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +10.62%
May-09-25 05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire) -5.88%
05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire)
May-07-25 08:00AM	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress (GlobeNewswire)
Apr-16-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-15-25 07:12AM	Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (Seeking Alpha)
Apr-10-25 09:24AM	Why Annexon Inc. (ANNX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 03:20PM	Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder (Benzinga) -7.79%
Apr-08-25 04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -5.52%
04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Apr-03-25 06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barre Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -6.63% -7.65%
06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77% -9.09%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-03-25 08:00AM	Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -9.47%
Feb-26-25 04:05PM	Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

J.D.Mr. Douglas E. Love Esq.

Executive VPMs. Jennifer Lew CPA

Executive VPDr. Ted Yednock Ph.D.

Chief Scientific Officer & Executive VPDr. Dean R. Artis Ph.D.

Chief Human Resources OfficerMs. Linda A. Fitzpatrick

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Love Douglas	PRESIDENT AND CEO	Sep 24 '26	Buy	3.83	26,065	99,829	390,476	Sep 25 04:15 PM
WIGGANS THOMAS G	Former Director	Aug 13 '26	Proposed Sale	5.30	2,000	10,596		Aug 13 03:34 PM
WIGGANS THOMAS G	Former Director	Jul 15 '26	Proposed Sale	6.32	2,000	12,630		Jul 15 04:19 PM
WIGGANS THOMAS G	Former Director	Jul 14 '26	Proposed Sale	5.61	1,000	5,605		Jul 14 01:56 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jun 11 '26	Option Exercise	1.85	30,646	56,698	184,807	Jun 15 04:15 PM
Satter Muneer A	Director	May 28 '26	Buy	5.41	613,497	3,319,019	10,342,134	May 29 05:21 PM
Carson William H.	Director	May 11 '26	Buy	5.78	8,000	46,240	78,405	May 13 04:30 PM
Carson William H.	Director	Apr 10 '26	Buy	6.20	8,000	49,600	70,405	Apr 14 04:16 PM
Carson William H.	Director	Mar 10 '26	Buy	5.67	8,000	45,360	62,405	Mar 12 04:31 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Mar 02 '26	Sale	5.43	5,820	31,603	123,582	Mar 04 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Mar 02 '26	Sale	5.42	4,339	23,517	182,625	Mar 04 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Mar 02 '26	Sale	5.42	5,566	30,168	154,161	Mar 04 04:30 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Mar 02 '26	Sale	5.43	5,894	32,004	180,093	Mar 04 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Mar 02 '26	Sale	5.42	5,565	30,162	170,700	Mar 04 04:30 PM
Yednock Ted	Officer	Mar 02 '26	Proposed Sale	5.42	5,566	30,181		Mar 02 05:05 PM
ARTIS DEAN RICHARD	Officer	Mar 02 '26	Proposed Sale	5.43	5,894	31,980		Mar 02 04:41 PM
Overdorf Michael	Officer	Mar 02 '26	Proposed Sale	5.42	4,339	23,530		Mar 02 04:16 PM
Dananberg Jamie	Officer	Mar 02 '26	Proposed Sale	5.43	5,820	31,579		Mar 02 04:05 PM
Lew Jennifer	Officer	Mar 02 '26	Proposed Sale	5.42	5,565	30,178		Mar 02 04:02 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '26	Sale	5.10	5,290	26,979	73,152	Feb 20 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	5.11	7,851	40,119	113,765	Feb 20 04:30 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '26	Sale	5.10	5,290	26,979	123,487	Feb 20 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '26	Sale	5.11	7,857	40,149	97,227	Feb 20 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '26	Sale	5.10	6,225	31,747	124,464	Feb 20 04:30 PM
Lew Jennifer	Officer	Feb 18 '26	Proposed Sale	5.11	7,851	40,119		Feb 18 03:39 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '26	Proposed Sale	5.10	5,290	26,990		Feb 18 03:38 PM
Yednock Ted	Officer	Feb 18 '26	Proposed Sale	5.11	7,857	40,122		Feb 18 03:29 PM
Overdorf Michael	Officer	Feb 18 '26	Proposed Sale	5.10	6,225	31,764		Feb 18 03:20 PM
Dananberg Jamie	Officer	Feb 18 '26	Proposed Sale	5.10	5,290	26,990		Feb 18 03:11 PM
Carson William H.	Director	Dec 30 '25	Buy	5.02	4,115	20,657	54,405	Jan 02 04:30 PM
Choi Jung	Director	Dec 01 '25	Buy	4.19	33,000	138,270	33,000	Dec 03 04:30 PM
Carson William H.	Director	Dec 01 '25	Buy	4.47	4,115	18,394	50,290	Dec 03 04:30 PM
Satter Muneer A	Director	Nov 21 '25	Buy	4.28	422,613	1,808,784	9,728,637	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 20 '25	Buy	4.48	400,000	1,792,000	9,306,024	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 19 '25	Buy	3.94	500,000	1,970,000	8,906,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 18 '25	Buy	3.18	500,000	1,590,000	8,406,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 17 '25	Buy	2.99	500,000	1,495,000	7,906,024	Nov 19 09:00 PM
Carson William H.	Director	Oct 30 '25	Buy	3.17	4,115	13,045	46,175	Oct 31 04:15 PM
Carson William H.	Director	Sep 30 '25	Buy	3.05	4,115	12,551	42,060	Oct 02 04:17 PM

Open in Screener

SKIL

Skillsoft Corp

5.95

Sep 25 • 3:59 PM ET -0.17 (-2.78%)

6.07

Aftermarket • 7:30 PM ET +0.12 (2.02%)

Consumer Defensive Education & Training Services USA Micro NYSE

Peers: FC LGCY APEI LINC LAUR LRN PRDO EDU LOPE BFAM

| Held by: VTI VXF IWC BUSM PRFZ AVSC

Index	-
Market Cap	54.14M
Enterprise Value	535.61M
Income	-136.09M
Sales	452.40M
Book/sh	-10.29
Cash/sh	10.23
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2247
IPO	Jul 26, 2019

P/E	-
Forward P/E	1.28
PEG	-
P/S	0.12
P/B	-
P/C	0.58
P/FCF	2.45
EV/EBITDA	5.16
EV/Sales	1.18
Quick Ratio	0.87
Current Ratio	0.87
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-15.49
EPS next Y	4.64
EPS next Q	1.34
EPS this Y	-0.24%
EPS next Y	12.08%
EPS next 5Y	-
EPS past 3/5Y	45.11% 1.82%
Sales past 3/5Y	-2.62% -
EPS Y/Y TTM	-10.94%
Sales Y/Y TTM	-13.66%
EPS Q/Q	39.92%
Sales Q/Q	-23.73%
Earnings	Sep 09 AMC
EPS/Sales Surpr.	40.96% -0.76%

Insider Own	48.61%
Insider Trans	2.69%
Inst Own	29.37%
Inst Trans	-6.40%
ROA	-12.87%
ROE	-439.57%
ROIC	-28.72%
Gross Margin	52.27%
Oper. Margin	-2.89%
Profit Margin	-30.08%
SMA20	-1.64%
SMA50	-14.69%
SMA200	-11.46%
Trades

Shs Outstand	9.06M
Shs Float	4.68M
Short Float	14.96%
Short Ratio	7.26
Short Interest	0.70M
52W High	18.45 -67.75%
52W Low	3.43 73.47%
Volatility	10.23% 12.09%
ATR (14)	0.67
RSI (14)	45.01
Beta	2.41
Rel Volume	0.28
Avg Volume	96.49K
Volume	26,850

Perf Week	-3.88%
Perf Month	-13.27%
Perf Quarter	-3.88%
Perf Half Y	44.42%
Perf YTD	-36.02%
Perf Year	-53.84%
Perf 3Y	-67.99%
Perf 5Y	-97.37%
Perf 10Y	-
Recom	2.00
Target Price	50.00
Prev Close	6.12
Price	5.95
Change %	-2.78%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-22	Resumed	Oppenheimer	Perform
May-05-22	Resumed	Barclays	Overweight	$7
Jan-28-22	Initiated	Colliers Securities	Buy	$13
Aug-17-21	Initiated	Oppenheimer	Perform
Aug-03-21	Initiated	Barclays	Overweight	$12
Jul-06-21	Initiated	Piper Sandler	Neutral	$11
Jun-24-21	Initiated	B. Riley Securities	Buy	$14
Jun-22-21	Initiated	Citigroup	Buy	$18

Sep-10-26 08:30AM	Skillsoft Corp. Q2 2027 Earnings Call Summary (Moby) -34.22%
08:00AM	Skillsoft LX Design Studio Reduces Custom Learning Content Development from Weeks to Days (Business Wire)
07:00AM	Skillsoft Corp (SKIL) (Q2 2027) Earnings Call Highlights: AI-Native Pivot Drives Margin ... (GuruFocus.com)
Sep-09-26 04:05PM	Skillsoft Reports Financial Results for the Second Quarter of Fiscal 2027 (Business Wire)
Aug-27-26 04:05PM	Skillsoft to Report Second Quarter Fiscal 2027 Financial Results on September 9 (Business Wire)
08:30AM	Loading…
Aug-04-26 08:30AM	Skillsoft Expands Skills Management Platform with AI Coach, Accelerating Connection Between Employee Learning and Performance (Business Wire) +7.61%
Aug-03-26 04:05PM	Skillsoft Appoints Matthew J. Cushing as Chief Legal Officer (Business Wire) +5.49%
Jul-08-26 04:15PM	Skillsoft Announces NYSE Acceptance of Continued Listing Compliance Plan (Business Wire)
Jul-06-26 06:30AM	Skillsoft Completes Sale of Global Knowledge Business, Advancing Focus on AI-Native Skills Management Platform (Business Wire) +6.37%
Jun-17-26 08:00AM	Skillsoft Helps Managers Turn Skills Intelligence Into Business Execution (Business Wire) +13.75%
Jun-12-26 04:30PM	Skillsoft Announces New Employee Inducement Grant Under NYSE Rule 303A.08 (Business Wire) +11.85%
Jun-10-26 08:30AM	Skillsoft Corp. Q1 2027 Earnings Call Summary (Moby) -13.70%
08:00AM	Only 1 in 4 Employees Feel Equipped for AI, Skillsoft Research Finds (Business Wire)
01:00AM	Skillsoft Corp (SKIL) Q1 2027 Earnings Call Highlights: Strong Platform Growth Amid Revenue ... (GuruFocus.com)
Jun-09-26 04:05PM	Skillsoft Reports Financial Results for the First Quarter and Full Year of Fiscal 2027 (Business Wire) -11.54%
04:05PM	Loading…
May-27-26 04:05PM	Skillsoft to Report First Quarter Fiscal 2027 Financial Results on June 9 (Business Wire)
May-20-26 05:25PM	Skillsoft Appoints Ron Kisling as Chief Financial Officer (Business Wire)
04:05PM	Skillsoft Announces Sale of Global Knowledge Business to Enduring Ventures (Business Wire)
Apr-21-26 08:00AM	Skillsoft Named a Strategic Leader in the Fosway 9Grid for Digital Learning Despite an Evolving Market (Business Wire) -8.80%
Apr-16-26 08:00AM	AI Skills Validation Surges 994% as Employees Seek to Prove Proficiency (Business Wire) +16.90%
Apr-08-26 08:30AM	Skillsoft Corp. Q4 2026 Earnings Call Summary (Moby) -12.02%
Apr-07-26 11:00PM	Skillsoft Corp (SKIL) Q4 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
04:05PM	Skillsoft Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2026 (Business Wire)
Apr-06-26 12:03PM	Cybersecurity Training: SANS Chief AI Officer & Chief of Research Rob T. Lee, Live at RSAC 2026 (Exec Edge)
Apr-02-26 08:00AM	AI-Powered Personalized Learning Surges 146% as Employees Build Skills in the Flow of Work (Business Wire)
Mar-31-26 06:45AM	Skillsoft Appoints Art Gilliland to Board of Directors (Business Wire)
Mar-30-26 05:00PM	Skillsoft Receives Continued Listing Standard Notice from NYSE (Business Wire) +7.34%
Mar-26-26 04:15PM	Skillsoft to Report Fourth Quarter and Full Year Fiscal 2026 Financial Results on April 7 (Business Wire)
Feb-27-26 12:56PM	Skillsoft vs. Duolingo: Which EdTech Stock Is a Smarter Bet Today? (Zacks) -5.84%
Feb-26-26 11:08AM	Can Percipio Define SKIL's Success in Capturing Market Share? (Zacks) +11.25%
08:00AM	Loading…
08:00AM	Skillsoft Named a Leader in Two IDC MarketScapes for IT Training Services in North America and Europe (Business Wire)
Feb-20-26 05:35PM	Skillsoft Announces New Employee Inducement Grant Under NYSE Rule 303A.08 (Business Wire) -5.16% -15.73%
Feb-11-26 10:39AM	Skillsoft Plummets 75% in a Year: Should You Hold or Fold the Stock? (Zacks) -13.77%
Feb-09-26 10:53AM	Best Growth Stocks to Buy for February 9th (Zacks)
Feb-04-26 08:00AM	Skillsoft Leads the Shift to Skills Management for Workforce Readiness (Business Wire)
04:47AM	Best Growth Stocks to Buy for February 4th (Zacks)
Feb-02-26 01:11PM	Coherent Q2 Earnings Preview: Buy Now or Wait for the Results? (Zacks) +7.07%
Jan-30-26 09:40AM	Are Business Services Stocks Lagging Agora (API) This Year? (Zacks) -6.51%
06:00AM	Best Growth Stocks to Buy for January 30th (Zacks)
04:04AM	Zacks Industry Outlook Highlights Figure Technology Solutions, Skillsoft and Adeia (Zacks)
Jan-29-26 12:48PM	3 Technology Services Stocks to Consider Amid Industry Turmoil (Zacks) +7.56%
Jan-28-26 05:33AM	Best Growth Stocks to Buy for January 28th (Zacks)
Jan-27-26 12:23PM	Skillsoft vs. Udemy: Which Online Learning Stock Is Worth Buying? (Zacks)
Jan-26-26 11:40AM	SKIL or SYM: Which Is the Better Value Stock Right Now? (Zacks) -6.43%
07:00AM	Best Growth Stocks to Buy for January 26th (Zacks)
Jan-23-26 10:13AM	Best Growth Stocks to Buy for January 23rd (Zacks)
Jan-20-26 10:07AM	Best Growth Stocks to Buy for January 20th (Zacks) -7.61%
08:21AM	Skillsoft's Prudent Expense Control: Means to Margin Resilience (Zacks)
03:12AM	Zacks.com featured highlights include Centerra Gold, Plains GP, Angi and Skillsoft (Zacks)
Jan-19-26 07:01AM	4 Value Stocks to Buy Now Amid Trump-Led Market Uncertainty (Zacks)
Jan-15-26 08:30AM	Skillsoft Appoints Bernard Barbour as Chief Technology and Product Officer (Business Wire) +12.29%
04:36AM	Best Growth Stocks to Buy for Jan. 15 (Zacks)
Jan-14-26 11:04AM	SKIL's AI-Native Strategy: Is Growth Painted in Its Long-Term Picture? (Zacks)
Jan-13-26 04:21AM	Best Growth Stocks to Buy for Jan. 13 (Zacks) -9.49%
Jan-09-26 12:34PM	Coherent's Robust Margin Expansion: Is This Key to Its Growth Engine? (Zacks) +8.99%
11:40AM	SKIL or APP: Which Is the Better Value Stock Right Now? (Zacks)
Jan-08-26 11:34AM	Skillsoft Slips 72% in a Year: How Should Investors Play the Stock? (Zacks) +9.74%
04:45AM	Best Growth Stocks to Buy for January 8th (Zacks)
Dec-29-25 11:52AM	SKIL vs. FUTU: Which Emerging Tech Stock Offers Better Returns? (Zacks) +9.21%
Dec-24-25 01:16PM	Skillsoft's Strategic Alternatives for GK: Can It Save the Core? (Zacks)
Dec-18-25 08:30AM	Skillsoft and edX Form Strategic Partnership to Expand University-Led Learning in The Skillsoft Platform (Business Wire) +22.22%
Dec-17-25 09:35AM	After Plunging 37% in 4 Weeks, Here's Why the Trend Might Reverse for Skillsoft (SKIL) (Zacks) +7.56%
Dec-16-25 08:00PM	Skillsoft Corp (SKIL) Q3 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com) +16.58%
11:40AM	SKIL vs. APP: Which Stock Is the Better Value Option? (Zacks)
Dec-11-25 06:13AM	Oracle stock dives after earnings, and other early market movers (MarketWatch) -21.53%
04:29AM	Stock Market Today: Dow futures flat, S&P 500 and Nasdaq lower after Fed rate-cut rally as Oracle earnings revive AI spending concerns; Broadcom results on tap (MarketWatch)
Dec-10-25 05:30PM	Skillsoft Corp. (SKIL) Surpasses Q3 Earnings Estimates (Zacks)
04:05PM	Skillsoft Reports Financial Results for the Third Quarter of Fiscal 2026 (Business Wire)
Dec-09-25 05:14PM	Skillsoft Global Knowledge Awarded a 2025 AWS Partner Award (Business Wire)
11:58AM	Skillsoft Plummets 69% YTD: Should You Buy the Stock or Hold Back? (Zacks)
Dec-08-25 05:15PM	Yext (YEXT) Q3 Earnings Beat Estimates (Zacks)
Nov-28-25 11:10AM	SKIL vs. DOCU: Which Tech Stock Holds More Promise for Investors? (Zacks)
Nov-26-25 08:00AM	Skillsoft to Report Third Quarter Fiscal 2026 Financial Results on December 10 (Business Wire) -18.73%
Nov-24-25 09:30AM	Skillsoft (SKIL) Surges 17.9%: Is This an Indication of Further Gains? (Zacks) +6.38%
05:13AM	Best Growth Stocks to Buy for Nov. 24 (Zacks)
Nov-21-25 05:51AM	Best Growth Stocks to Buy for Nov. 21st (Zacks) +17.86%
Nov-20-25 07:40AM	Maximus (MMS) Q4 Earnings and Revenues Lag Estimates (Zacks) -8.47%
Nov-19-25 11:40AM	SKIL or CLMB: Which Is the Better Value Stock Right Now? (Zacks)
08:15AM	Is Percipio the Key to Reshaping Skillsoft's Market Positioning? (Zacks)
06:35AM	Best Growth Stocks to Buy for Nov. 19th (Zacks)
Nov-17-25 08:10AM	Arbe Robotics Ltd. (ARBE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-13-25 01:24PM	SKIL Plummets 53% in 6 Months: Should Investors Buy the Dip Now? (Zacks)
04:53AM	Best Growth Stocks to Buy for Nov. 13 (Zacks)
Nov-12-25 07:30PM	SKYX Platforms Corp. (SKYX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -11.15%
Nov-10-25 05:30PM	Viant Technology (DSP) Q3 Earnings Miss Estimates (Zacks)
Nov-07-25 04:35AM	Best Growth Stocks to Buy for Nov. 7 (Zacks)
Nov-03-25 11:40AM	SKIL vs. AMPL: Which Stock Is the Better Value Option? (Zacks)
Oct-30-25 09:23AM	Best Growth Stocks to Buy for Oct. 30th (Zacks)
Oct-28-25 07:44AM	Best Growth Stocks to Buy for Oct. 28th (Zacks) -6.90%
Oct-27-25 08:50AM	Looking for a Fast-paced Momentum Stock at a Bargain? Consider Skillsoft (SKIL) (Zacks) -14.16%
Oct-23-25 06:16AM	Best Growth Stocks to Buy for Oct. 23 (Zacks)
Oct-21-25 06:04AM	Best Growth Stocks to Buy for Oct. 21 (Zacks)
Oct-17-25 11:40AM	SKIL or MLNK: Which Is the Better Value Stock Right Now? (Zacks) +9.21%
11:33AM	Skillsoft (SKIL) Moves 7.0% Higher: Will This Strength Last? (Zacks)
09:27AM	Best Growth Stocks to Buy for Oct. 17th (Zacks)
Oct-15-25 01:38PM	Rezolve AI Stock Soars 310% in 6 Months: Time to Buy or Hold? (Zacks)
09:25AM	Best Growth Stocks to Buy for Oct. 15th (Zacks)
07:17AM	5 Technology Services Stocks to Buy for Stellar Returns in Q4 (Zacks)
Oct-14-25 09:25AM	Best Growth Stocks to Buy for Oct. 14th (Zacks)
Oct-13-25 05:27AM	Zacks Value Investor Highlights: SKIL, PINS and MU (Zacks)

Skillsoft Corp. engages in the provision of enterprise learning solutions. It operates through the Skillsoft Content and Global Knowledge segments. The Skillsoft Content segment is involved in the sale, marketing, and delivery of its content learning solutions, in areas such as Leadership and Business, Technology and Developer, and Compliance. It also includes technical skill areas assumed in the Codecademy acquisition. The Global Knowledge segment offers training solutions covering information technology and business skills for corporations and their employees. The company was founded on August 8, 1998 and is headquartered in Nashua, NH.

Executive Chairman & CEOMr. Ronald W. Hovsepian

AdvisorMr. John Wilbert Frederick CPA

Chief Revenue OfficerMr. Matthew Glitzer

Chief Financial OfficerMr. Ronald W. Kisling

Chief Transformation & Operations OfficerMr. Jose Almandoz

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HOVSEPIAN RONALD W	CEO & Executive Chair	Sep 23 '26	Buy	5.93	11,196	66,415	382,267	Sep 25 04:19 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Sep 21 '26	Buy	6.10	8,325	50,772	371,071	Sep 23 04:30 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Sep 18 '26	Buy	6.52	12,777	83,275	362,746	Sep 21 04:34 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Sep 17 '26	Buy	6.17	2,691	16,590	349,969	Sep 21 04:34 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Sep 15 '26	Buy	5.46	4,508	24,625	345,857	Sep 17 04:59 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Sep 16 '26	Buy	5.90	1,421	8,378	347,278	Sep 17 04:59 PM
FRANKOLA JIM	Director	Sep 15 '26	Buy	5.14	25,000	128,595	132,736	Sep 17 04:57 PM
Swiniarski Keith C.	Chief Accounting Officer	Sep 01 '26	Option Exercise	0.00	500	0	4,183	Sep 03 05:46 PM
Semel Scott	Interim CLO & General Counsel	Aug 01 '26	Option Exercise	0.00	4,000	0	25,994	Aug 05 07:07 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Jul 16 '26	Option Exercise	0.00	31,250	0	341,349	Jul 20 05:37 PM
Swiniarski Keith C.	Chief Accounting Officer	Jul 01 '26	Option Exercise	0.00	625	0	3,835	Jul 02 07:37 PM
Semel Scott	Interim CLO & General Counsel	Jul 01 '26	Option Exercise	0.00	4,000	0	23,168	Jul 02 07:33 PM
Klein Michael Stuart	Director	Jun 25 '26	Option Exercise	0.00	12,430	0	39,336	Jun 26 06:19 PM
Gilliland Arthur W	Director	Jun 25 '26	Option Exercise	0.00	6,250	0	6,250	Jun 26 06:16 PM
FRANKOLA JIM	Director	Jun 25 '26	Option Exercise	0.00	12,430	0	107,736	Jun 26 06:12 PM
FRANKOLA JIM	Director	Jun 15 '26	Buy	6.05	27,000	163,350	95,306	Jun 16 06:35 PM
FRANKOLA JIM	Director	Jun 12 '26	Buy	6.06	23,000	139,380	68,306	Jun 16 06:35 PM
Semel Scott	Interim CLO & General Counsel	Jun 01 '26	Option Exercise	0.00	4,000	0	20,342	Jun 03 06:06 PM
Swiniarski Keith C.	Chief Accounting Officer	May 01 '26	Option Exercise	0.00	813	0	3,393	May 05 07:31 PM
Semel Scott	Interim CLO & General Counsel	May 01 '26	Option Exercise	0.00	4,000	0	17,516	May 05 07:29 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	May 01 '26	Option Exercise	0.00	22,523	0	310,099	May 05 07:25 PM
Glitzer Matthew	CHIEF REVENUE OFFICER	May 01 '26	Option Exercise	0.00	25,313	0	45,006	May 05 07:20 PM
Frederick John W.	Chief Financial Officer	May 01 '26	Option Exercise	0.00	17,750	0	27,745	May 05 07:18 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Apr 16 '26	Option Exercise	0.00	31,250	0	296,747	Apr 20 06:17 PM
Semel Scott	Interim CLO & General Counsel	Apr 01 '26	Option Exercise	0.00	4,000	0	14,690	Apr 03 05:33 PM
Swiniarski Keith C.	Principal Accounting Officer	Mar 01 '26	Option Exercise	0.00	938	0	2,913	Mar 03 06:12 PM
Semel Scott	Interim CLO & General Counsel	Mar 01 '26	Option Exercise	0.00	4,000	0	11,842	Mar 03 06:06 PM
Semel Scott	Interim CLO & General Counsel	Feb 01 '26	Option Exercise	0.00	4,000	0	9,228	Feb 02 07:12 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Jan 16 '26	Option Exercise	0.00	31,250	0	265,497	Jan 21 05:53 PM
Semel Scott	Interim CLO & General Counsel	Jan 01 '26	Option Exercise	0.00	4,000	0	6,614	Jan 05 06:27 PM
Semel Scott	Interim CLO & General Counsel	Dec 01 '25	Option Exercise	0.00	4,000	0	4,000	Dec 10 06:31 PM
HOVSEPIAN RONALD W	CEO & Executive Chair	Oct 16 '25	Option Exercise	0.00	31,250	0	234,247	Oct 20 05:05 PM
Glitzer Matthew	CHIEF REVENUE OFFICER	Oct 01 '25	Option Exercise	0.00	2,813	0	26,096	Oct 03 04:57 PM

Open in Screener

ADAG

Adagene Inc ADR

2.93

Sep 25 • 3:59 PM ET -0.05 (-1.68%)

2.99

Aftermarket • 7:30 PM ET +0.06 (2.05%)

Healthcare Biotechnology China Micro NASD

Peers: CAMP CNTN IFRX PLYX PRQR RNA TLSA KPTI CNTX TENX

| Held by: PGJ EWX

Index	-
Market Cap	196.72M
Enterprise Value	91.45M
Income	-20.56M
Sales	9.32M
Book/sh	1.33
Cash/sh	1.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	128
IPO	Feb 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	21.11
P/B	2.20
P/C	1.54
P/FCF	-
EV/EBITDA	-
EV/Sales	9.81
Quick Ratio	5.02
Current Ratio	5.02
Debt/Eq	0.06
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.38
EPS next Y	-0.63
EPS next Q	-0.28
EPS this Y	-61.90%
EPS next Y	-29.71%
EPS next 5Y	-28.17%
EPS past 3/5Y	41.25% 21.03%
Sales past 3/5Y	-6.07% 61.40%
EPS Y/Y TTM	41.48%
Sales Y/Y TTM	8906.15%
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	- -

Insider Own	18.78%
Insider Trans	0.38%
Inst Own	18.90%
Inst Trans	41.61%
ROA	-20.55%
ROE	-28.57%
ROIC	-19.17%
Gross Margin	94.22%
Oper. Margin	-240.31%
Profit Margin	-220.66%
SMA20	-12.10%
SMA50	-18.89%
SMA200	-11.62%
Trades

Shs Outstand	67.14M
Shs Float	54.73M
Short Float	3.84%
Short Ratio	7.71
Short Interest	2.10M
52W High	4.85 -39.59%
52W Low	1.30 125.38%
Volatility	7.42% 8.01%
ATR (14)	0.27
RSI (14)	34.54
Beta	0.54
Rel Volume	0.73
Avg Volume	272.60K
Volume	197,662

Perf Week	-11.48%
Perf Month	-23.90%
Perf Quarter	-30.07%
Perf Half Y	-29.23%
Perf YTD	55.03%
Perf Year	45.05%
Perf 3Y	132.54%
Perf 5Y	-79.37%
Perf 10Y	-
Recom	1.29
Target Price	9.74
Prev Close	2.98
Price	2.93
Change %	-1.68%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-26	Initiated	Chardan Capital Markets	Buy	$9
Nov-24-25	Initiated	Guggenheim	Buy	$9
Aug-06-25	Initiated	Leerink Partners	Outperform	$7
Jan-31-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-25-21	Initiated	China Renaissance	Buy	$40.57
Mar-08-21	Initiated	Morgan Stanley	Overweight	$34
Mar-08-21	Initiated	Jefferies	Buy	$33
Mar-08-21	Initiated	Goldman	Buy	$29

Sep-22-26 08:00AM	Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager (GlobeNewswire)
Sep-10-26 08:00AM	Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody Technology (GlobeNewswire)
Sep-09-26 08:00AM	Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody Antibody-Drug Conjugate Candidates (GlobeNewswire) -6.30%
Aug-20-26 08:00AM	Adagene to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-12-26 07:30AM	Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
08:30AM	Loading…
May-12-26 08:30AM	Adagene to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Apr-17-26 04:01PM	Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types (GlobeNewswire)
Apr-14-26 07:00AM	Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board (GlobeNewswire)
Apr-02-26 07:10AM	Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs (GlobeNewswire) -13.45%
07:01AM	Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) (GlobeNewswire)
07:00AM	Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response (GlobeNewswire)
Apr-01-26 05:00PM	Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.60%
Mar-17-26 04:35PM	Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA (GlobeNewswire)
Feb-25-26 05:25PM	Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk (MarketBeat) -5.67%
Feb-17-26 09:27AM	Adagene to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
07:48AM	Loading…
Feb-16-26 07:48AM	Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders (Zacks)
Jan-23-26 08:00AM	Adagene Provides Business Update and 2026 Objectives (GlobeNewswire) +22.66%
Dec-17-25 08:43AM	FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug (Zacks)
Dec-16-25 07:00AM	Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) (GlobeNewswire) +13.77%
Nov-13-25 07:00AM	Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody Technology (GlobeNewswire)
Oct-31-25 07:00AM	Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Microsatellite Stable Colorectal Cancer (GlobeNewswire) -7.29%
Sep-30-25 12:00PM	All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy (Zacks)
Sep-25-25 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Sep-16-25 08:00AM	Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate (GlobeNewswire)
Sep-08-25 04:59PM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) +8.64%
Sep-05-25 09:55AM	Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China (GlobeNewswire)
Sep-03-25 09:05AM	Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor (GlobeNewswire)
Aug-26-25 08:05AM	Adagene to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-21-25 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks) +10.14%
Aug-12-25 04:05PM	Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) -16.59% -13.61%
07:00AM	Loading…
Jul-15-25 07:00AM	Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA (GlobeNewswire)
Jul-08-25 07:00AM	Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate (GlobeNewswire)
Jul-01-25 07:00AM	Adagene announces up to $25 million strategic investment from Sanofi (GlobeNewswire) -5.13%
Jun-03-25 09:40AM	Is McKesson (MCK) Outperforming Other Medical Stocks This Year? (Zacks)
May-27-25 07:30AM	Adagene to Present at Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-22-25 05:05PM	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.00%
Apr-28-25 08:00AM	Adagene Appoints John Maraganore, Ph.D. as Executive Advisor (GlobeNewswire)
Apr-23-25 10:05AM	Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-07-25 08:00AM	Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum (GlobeNewswire)
Mar-24-25 08:00AM	Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.04%
Mar-13-25 08:00AM	Adagene to Present at 11th Annual Immuno-Oncology 360 Summit (GlobeNewswire)
Mar-06-25 08:00AM	Adagene to Present at Leerink's Global Healthcare Conference 2025 (GlobeNewswire)
Feb-27-25 08:00AM	Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer (GlobeNewswire)
Jan-27-25 07:00AM	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-21-25 05:00PM	Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-14-25 08:00AM	Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 (GlobeNewswire)
Jan-08-25 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.34%
Dec-06-24 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Nov-20-24 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.86%
Nov-07-24 10:01AM	Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire)
Oct-09-24 06:00AM	Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-16-24 03:01AM	Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) -21.20%
Sep-11-24 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Aug-29-24 07:00AM	Adagene to Participate in Investor Conferences in September (GlobeNewswire)
Aug-26-24 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-25-24 04:05PM	Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update (GlobeNewswire) -7.50%
Jul-12-24 07:00AM	Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September (GlobeNewswire)
May-22-24 04:45PM	Adagene to Present at Investor Conferences in June (GlobeNewswire) +6.90%
Mar-29-24 09:00AM	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-24 04:01PM	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board (GlobeNewswire)
Feb-27-24 08:00AM	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-09-24 06:00AM	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with KEYTRUDA (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) +5.14%
Jan-17-24 07:00AM	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (PR Newswire) +5.82%
Jan-16-24 05:01PM	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) +19.24%
Jan-04-24 05:00AM	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium (GlobeNewswire)
Nov-03-23 12:00PM	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 at SITC 2023 (GlobeNewswire)
Oct-30-23 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
Oct-13-23 09:40AM	Are Medical Stocks Lagging Medpace (MEDP) This Year? (Zacks)
Oct-12-23 08:00AM	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.04%
Sep-27-23 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks) +10.14%
Sep-07-23 10:45PM	Adagene to Present at Investor and Scientific Conferences in September (PR Newswire)
09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Aug-31-23 07:32AM	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update (GlobeNewswire) +15.25%
May-25-23 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.22%
May-04-23 09:00AM	Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate (GlobeNewswire)
Apr-28-23 07:00AM	Adagene Announces Updates to its Board of Directors (GlobeNewswire)
Apr-18-23 09:17AM	Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors (GlobeNewswire)
Mar-31-23 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
06:34AM	Adagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021) (Simply Wall St.)
Mar-28-23 04:30PM	Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +5.84%
Mar-14-23 06:00PM	Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April (GlobeNewswire) +5.15% +11.89%
Mar-05-23 07:39PM	Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board (GlobeNewswire)
Jan-09-23 07:00AM	Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial (GlobeNewswire) +11.25%
Jan-05-23 04:01PM	Adagene to Present at the Biotech Showcase 2023 in San Francisco on January 9 (GlobeNewswire) +5.11% +11.11%
Dec-16-22 06:30AM	Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roches Standard-of-Care for First-Line Advanced Liver Cancer (GlobeNewswire) +10.61%
Nov-21-22 04:05PM	Adagene Appoints Cuong Do to Board of Directors and Audit Committee (GlobeNewswire)
Nov-10-22 09:05AM	Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors (GlobeNewswire)
Oct-11-22 04:03PM	Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody, ADG116, at Upcoming Society for Immunotherapy of Cancers (SITC) Annual Meeting in November (GlobeNewswire) -7.63% +6.61%
Sep-10-22 04:13AM	Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors (GlobeNewswire)
Aug-30-22 05:25PM	Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates (GlobeNewswire)
Jun-29-22 04:05PM	Adagene Announces Authorization of Share Repurchase Program up to US$10 Million (GlobeNewswire)
May-26-22 09:30PM	Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels (PR Newswire)
May-12-22 07:00AM	Adagene to Participate in Investor Conferences in May and June (GlobeNewswire)
May-02-22 06:06AM	Shareholders in Adagene (NASDAQ:ADAG) are in the red if they invested a year ago (Simply Wall St.)
Apr-08-22 01:09PM	Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Apr-03-22 02:34PM	10 Best Non-Tech Chinese Stocks to Buy Now (Insider Monkey)
Mar-31-22 08:30AM	Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-17-22 10:42AM	Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo (Zacks)
Mar-16-22 10:00AM	Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors (Benzinga)
07:00AM	Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab (PR Newswire)

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Co- FounderDr. Peter P. Luo Ph.D.

CFO & DirectorMr. Man Kin Tam M.B.A.

Executive Director & Head of Human ResourcesMs. Ling Zhou

Chief Manufacturing OfficerDr. Qinghai Zhao Ph.D.

Chief Strategy OfficerMr. Mickael Chane-Du

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tam Man Kin	Chief Financial Officer	Sep 23 '26	Buy	3.00	2,000	6,000	12,000	Sep 25 06:23 PM
Luo Peter	Chief Executive Officer	Sep 16 '26	Buy	3.15	20,290	63,980	88,535	Sep 17 06:11 AM
GU CHUNFANG	Officer	Aug 20 '26	Proposed Sale	3.95	40,000	158,000		Aug 19 10:22 AM
DO CUONG V	Director	Aug 14 '26	Buy	3.75	2,000	7,500	2,000	Aug 18 06:11 PM
Luo Peter	Chief Executive Officer	Aug 04 '26	Buy	3.65	22,966	83,746	67,966	Aug 06 06:15 PM
Luo Peter	Chief Executive Officer	Aug 05 '26	Buy	3.65	279	1,018	68,245	Aug 06 06:15 PM

Open in Screener

CMPX

Compass Therapeutics Inc

1.13

Sep 25 • 3:59 PM ET -0.00 (-0.44%)

1.12

Aftermarket • 7:53 PM ET -0.01 (-0.88%)

Healthcare Biotechnology USA Micro NASD

CMPX Compass Therapeutics Inc daily Stock Chart

Peers: ARVN BBOT CGEM ALLO RIGL GERN CTMX JANX KURA XNCR

| Held by: VTI XBI VXF IWM FESM VTWO IWN VHT IWC VTWV

Index	RUT
Market Cap	203.50M
Enterprise Value	33.25M
Income	-73.45M
Sales	0.00M
Book/sh	0.92
Cash/sh	1.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	39
IPO	Apr 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.23
P/C	1.13
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.22
Current Ratio	11.22
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-0.40
EPS next Y	-0.56
EPS next Q	-0.13
EPS this Y	-18.10%
EPS next Y	-12.62%
EPS next 5Y	-0.43%
EPS past 3/5Y	-4.18% 5.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	10.44%
Sales Y/Y TTM	-100.00%
EPS Q/Q	6.33%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-17.43% 100.00%

Insider Own	24.17%
Insider Trans	0.01%
Inst Own	73.26%
Inst Trans	-0.39%
ROA	-47.87%
ROE	-56.66%
ROIC	-42.20%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-41.46%
SMA50	-45.64%
SMA200	-69.73%
Trades

Shs Outstand	180.09M
Shs Float	136.57M
Short Float	30.50%
Short Ratio	12.19
Short Interest	41.65M
52W High	6.88 -83.58%
52W Low	1.10 2.73%
Volatility	9.97% 6.32%
ATR (14)	0.14
RSI (14)	18.49
Beta	0.88
Rel Volume	1.03
Avg Volume	3.42M
Volume	3,532,924

Perf Week	-40.53%
Perf Month	-53.50%
Perf Quarter	-45.67%
Perf Half Y	-78.80%
Perf YTD	-78.96%
Perf Year	-67.62%
Perf 3Y	-44.06%
Perf 5Y	-67.71%
Perf 10Y	-
Recom	1.40
Target Price	5.50
Prev Close	1.13
Price	1.13
Change %	-0.44%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-26	Downgrade	Wedbush	Outperform → Neutral	$1
Jul-01-26	Resumed	Ladenburg Thalmann	Buy	$5
Apr-28-26	Downgrade	Raymond James	Outperform → Mkt Perform
Feb-13-26	Initiated	Craig Hallum	Buy	$15
Jan-05-26	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform	$10
Dec-03-25	Initiated	Cantor Fitzgerald	Overweight
Dec-03-25	Initiated	Canaccord Genuity	Buy	$10
Jul-01-25	Resumed	Raymond James	Outperform	$9
Apr-02-25	Upgrade	Leerink Partners	Market Perform → Outperform	$6
Feb-24-25	Initiated	Guggenheim	Buy	$12
Feb-19-25	Initiated	Piper Sandler	Overweight	$12
Dec-23-24	Initiated	D. Boral Capital	Buy	$32
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform	$5 → $4
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$5
Jan-31-23	Initiated	Jefferies	Buy	$8
Jan-27-23	Initiated	Stifel	Buy	$9
May-23-22	Resumed	H.C. Wainwright	Buy	$12
Mar-15-22	Initiated	Ladenburg Thalmann	Buy	$7
Jan-19-22	Initiated	B. Riley Securities	Buy	$10

Show Previous Ratings

Sep-23-26 09:49AM	Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls (The Fly) -5.65%
09:44AM	Compass Therapeutics FDA Setback Raises Concerns On Wall Street H.C. Wainwright Calls Tovecimig Filing Strategy Risky (Stocktwits)
Sep-22-26 07:07PM	CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug Wedbush Sees Another 19% Downside (Stocktwits) -31.87%
10:43AM	CMPX Stock Crashes To Over 2-Year Lows Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing (Stocktwits)
08:30AM	Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback (GlobeNewswire)
07:30AM	Loading…
Aug-06-26 07:30AM	Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +5.29%
Jul-17-26 10:42AM	Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 (GlobeNewswire)
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
May-28-26 07:30AM	Compass Therapeutics to Participate in Upcoming June Investor Events (GlobeNewswire) +6.17%
May-21-26 05:00PM	Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting (GlobeNewswire) +7.25%
May-12-26 07:30AM	Compass Therapeutics to Participate in Upcoming May Investor Events (GlobeNewswire)
May-05-26 07:30AM	Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-26 10:30AM	BC-Most Active Stocks (Associated Press)
10:19AM	Micron initiated, Rambus downgraded: Wall Street's top analyst calls (The Fly)
07:21AM	Compass Therapeuticss stock crashes after OS miss in BTC trial (Clinical Trials Arena)
12:29PM	Loading…
Apr-27-26 12:29PM	This Biotech Stock Is Down 61%. How a Cancer Trial Was Ruined by Its Own Design. (Barrons.com) -64.41%
10:30AM	BC-Most Active Stocks (Associated Press)
07:30AM	Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer (GlobeNewswire)
Apr-24-26 04:00PM	Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer (GlobeNewswire)
Mar-05-26 07:30AM	Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-17-26 09:40AM	Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-29-26 09:40AM	Are Medical Stocks Lagging ResMed (RMD) This Year? (Zacks)
Jan-27-26 09:55AM	Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High? (Zacks)
Jan-19-26 05:00PM	Compass Therapeutics, Inc. (CMPX): A Bull Case Theory (Insider Monkey)
Jan-06-26 08:00AM	Compass Therapeutics Provides Corporate Update (GlobeNewswire)
Jan-05-26 04:30PM	Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Compass Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
Dec-21-25 07:31AM	Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment (Insider Monkey)
Dec-19-25 09:40AM	Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? (Zacks)
Dec-17-25 07:30AM	Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -5.34%
09:55AM	Loading…
Dec-12-25 09:55AM	Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet (Zacks)
Dec-08-25 12:00PM	Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy (Zacks)
Dec-03-25 09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Dec-01-25 01:04AM	Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement (Insider Monkey) -5.86%
Nov-26-25 09:55AM	Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade (Zacks) +7.58%
Nov-25-25 08:00AM	Compass Therapeutics to Participate in Upcoming December Investor Events (GlobeNewswire)
Nov-24-25 05:08AM	Zacks.com featured highlights include Orla Mining, FIGS and Compass Therapeutics (Zacks)
Nov-20-25 03:00PM	2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out! (Zacks)
Nov-18-25 06:17AM	Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development (Insider Monkey)
Nov-05-25 07:30AM	Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 09:00AM	Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-03-25 08:00AM	Compass Therapeutics to Participate in Upcoming November Investor Events (GlobeNewswire)
Oct-30-25 11:29PM	Piper Sandler Remains Bullish on Compass Therapeutics (CMPX) (Insider Monkey)
Sep-11-25 03:31AM	Guggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer Pipeline (Insider Monkey)
Sep-02-25 12:57AM	Piper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update (Insider Monkey)
Aug-26-25 08:00AM	Compass Therapeutics to Participate in Upcoming September Investor Events (GlobeNewswire)
Aug-20-25 12:22AM	Compass Therapeutics (CMPX) Rated 'Outperform' amid Clinical Pipeline Development (Insider Monkey)
Aug-12-25 10:28PM	Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering (GlobeNewswire) -5.09%
04:01PM	Compass Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:03AM	Compass Therapeutics Inc (CMPX) Q2 2025 Earnings Call Highlights: Promising Clinical Advances ... (GuruFocus.com)
Aug-11-25 07:00AM	Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +23.70%
Aug-08-25 04:01PM	Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025 (GlobeNewswire)
Jul-25-25 12:09PM	Stifel Keeps Buy Rating on Compass Therapeutics (CMPX) (Insider Monkey)
Jul-22-25 11:03AM	Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline (Insider Monkey)
May-28-25 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 08:00AM	Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-25 08:00AM	Compass Therapeutics to Participate in Upcoming May Investor Events (GlobeNewswire) -9.14%
Apr-28-25 08:00AM	Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-21-25 08:00AM	Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer (GlobeNewswire)
Apr-02-25 04:05PM	Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) -24.55% -5.03%
Apr-01-25 07:00AM	Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer (GlobeNewswire) +17.89%
Mar-31-25 04:05PM	Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer (GlobeNewswire)
Mar-27-25 10:20AM	Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-02-25 10:22AM	Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-27-25 08:00AM	Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-29-25 08:00AM	Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate (GlobeNewswire) +30.07%
Dec-10-24 08:00AM	Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer (GlobeNewswire) +7.88%
Dec-02-24 08:00AM	Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 08:30AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) -5.59%
Nov-12-24 08:00AM	Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire) -5.79%
Nov-08-24 10:05AM	Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-04-24 10:31AM	Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-12-24 08:00AM	Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 08:00AM	Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire) -6.52%
Aug-06-24 08:00AM	Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer (GlobeNewswire)
Jul-10-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why (Zacks) +9.94%
May-30-24 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -7.48%
May-28-24 04:10PM	Compass Therapeutics Announces CEO Transition (GlobeNewswire)
May-23-24 05:05PM	Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire)
May-14-24 08:00AM	Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-13-24 02:53PM	CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-25-24 08:00AM	Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated (GlobeNewswire)
Apr-16-24 08:00AM	Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors (GlobeNewswire)
Apr-12-24 08:00AM	Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference (GlobeNewswire)
Apr-10-24 08:00AM	Compass Therapeutics to Participate in the Stifel Targeted Oncology Days (GlobeNewswire)
Apr-09-24 12:00PM	Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-21-24 10:54PM	CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +5.66%
09:00AM	Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-29-24 08:00AM	Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 08:00AM	Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial (GlobeNewswire)
Feb-08-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know (Zacks) +8.21%
Jan-05-24 08:00AM	Compass Therapeutics Provides Corporate Update (GlobeNewswire) +5.16%
Nov-09-23 08:17AM	Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) -6.40%
07:30AM	Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-30-23 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-03-23 08:00AM	Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Ph.D.Dr. Thomas J. Schuetz M.D.

M.B.A.Mr. Barry Shin J.D.

Senior VPMr. Jonathan E. Anderman J.D.

Senior VP & Chief Accounting OfficerMr. Neil L. Lerner CPA

Chief Scientific OfficerMr. Bing Gong Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lerner Neil	Chief Accounting Officer	Sep 24 '26	Buy	1.14	2,500	2,850	400,000	Sep 25 08:01 AM

MX

MagnaChip Semiconductor Corp

URG

Ur-Energy Inc

ANNX

Annexon Inc

SKIL

Skillsoft Corp

ADAG

Adagene Inc ADR

CMPX

Compass Therapeutics Inc

Upgrade your Finviz experience